Companion Animal Veterinary Vaccines Market Report 2026

Companion Animal Veterinary Vaccines Market Overview

• Companion Animal Veterinary vaccines market size has reached to $3.94 billion in 2025 • Expected to grow to $5.38 billion in 2030 at a compound annual growth rate (CAGR) of 6.5% • Growth Driver: Companion Animal Health Expenditure A Propeller For Vaccine Market Growth • Market Trend: Innovative Vaccine Introductions Driving Revenue In Companion Animal Vaccine Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Companion Animal Veterinary Vaccines Market?

Companion animal vaccines are substances that are used to stimulate the production of antibodies and provide immunity against one or several diseases in pets such as dogs, birds, and cats. They are also used to improve food digestion, enhance immunity, enable animals to gain fat and weight, and generate good quality meat that is harvested for commercial purposes. The main products of companion animal veterinary vaccines are inactivated, live attenuated, recombinant, and other products. A recombinant vaccine is one that was created using recombinant DNA technology. This entails inserting DNA encoding an antigen (such as a bacterial surface protein) that triggers an immunological response into bacterial or mammalian cells, expressing the antigen in these cells, and then purifying it from them. The products are administered through oral, parenteral, and other routes of administration and are distributed through veterinary hospitals, veterinary clinics, pharmacies, drug stores, and other distribution channels.

What Is The Companion Animal Veterinary Vaccines Market Growth Forecast?

The companion animal veterinary vaccines market size is expected to see strong growth in the next few years. It will grow to $5.38 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to increasing pet humanization trends, rising expenditure on pet healthcare, advancements in vaccine technology, growth in urban pet ownership, supportive government animal health initiatives. Major trends in the forecast period include rising adoption of combination vaccines, increasing focus on preventive pet healthcare, growth in vaccination coverage for companion animals, expansion of recombinant and dna-based vaccines, rising demand for oral and less invasive vaccination routes.

Global Companion Animal Veterinary Vaccines Market Segmentation

1) By Product: Inactivated, Live Attenuated, Recombinant, Other Products 2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration 3) By Distribution Channel: Veterinary Hospitals, Veterinary Clinics, Pharmacies And Drug Stores, Other Distribution Channels Subsegments: 1) By Inactivated: Inactivated Canine Vaccines, Inactivated Feline Vaccines, Inactivated Vaccine Combinations 2) By Live Attenuated: Live Attenuated Canine Vaccines, Live Attenuated Feline Vaccines, Live Attenuated Vaccine Combinations 3) By Recombinant: Recombinant Canine Vaccines, Recombinant Feline Vaccines, Recombinant Vaccine Combinations 4) By Other Products: DNA Vaccines, Subunit Vaccines, Toxoid Vaccines

What Is The Driver Of The Companion Animal Veterinary Vaccines Market?

The increasing spending on pet health is expected to propel the growth of the companion animal veterinary vaccines market going forward. Pet health refers to the overall well-being and condition of an animal, whether it is a dog, cat, bird, small mammal, or any other domesticated pet. The increasing spending on pet health is rising due to pet owners becoming more aware of the importance of preventive care and advanced treatments to ensure their pets live longer, healthier lives. The companion animal veterinary vaccines market supports increasing spending on pet health by providing essential vaccines that prevent diseases and reduce long-term veterinary costs, encouraging pet owners to invest more in their pets' well-being. For instance, in February 2025, according to the report published by pet business professor, a US-based government agency, U.S. pet owners spent approximately $13.42 billion on pet services up 8.5 % from 2022’s $12.36 billion reflecting sustained growth in grooming, boarding, and care utilization. Therefore, increasing spending on pet health is driving the growth of companion animal veterinary vaccines industry.

Key Players In The Global Companion Animal Veterinary Vaccines Market

Major companies operating in the companion animal veterinary vaccines market are C.H. Boehringer Sohn AG & Co. KG, Heska Corp., Merck and Co. Inc., Elanco Animal Health, Zoetis Inc., Ceva Sante Animale SA, Vetoquinol SA, Hipra India Pvt Ltd, Bimeda Animal Health Limited, Nexvet Biopharma plc, Laboratorios Hipra SA, Dechra Pharmaceuticals PLC, CZ Veterinaria SA, Virbac, Boehringer Ingelheim Animal Health, Indian Immunologicals Limited, HIPRA SA, IDT Biologika GmbH, Ourofino Saude Animal, Zydus Animal Health, Meiji Seika Pharma Co Ltd, Parnell Pharmaceuticals, Kindred Biosciences Inc, Hester Biosciences Limited

Global Companion Animal Veterinary Vaccines Market Trends and Insights

Major companies operating in the companion animal vaccine market are introducing new vaccines, such as recombinant DNA vaccines, to improve the effectiveness and safety of immunizations for pets. A recombinant DNA vaccine refers to a type of vaccine created by inserting genetic material (DNA) from a pathogen, such as a virus or bacterium, into a harmless organism or vector. For instance, in March 2024, Zendal Group, a Spain-based biotechnology company, launched Neoleish, the first recombinant DNA vaccine specifically designed to combat canine leishmaniasis, developed in collaboration with the Spanish National Research Council (CSIC). Officially presented at the XLI Annual Congress of the Madrid Association of Veterinarians of Companion Animals, Neoleish has demonstrated over 90% efficacy in reducing infection risk from the Leishmania infantum parasite.

What Are Latest Mergers And Acquisitions In The Companion Animal Veterinary Vaccines Market?

In June 2023, Mars Inc., a US-based manufacturing company, acquired Heska Corp. for an amount of $1.3 billion. This acquisition strengthens Mars Petcare's veterinary care capabilities and advances its commitment to improving pet health. Heska is now part of Mars Petcare's science and diagnostics division, including antech diagnostics. The integration enhances diagnostic services for veterinary professionals and pet owners, expanding access to advanced diagnostic technologies and accelerating research and development in veterinary healthcare. Heska Corp is a US-based veterinary services company specializes in developing, manufacturing, and commercializing advanced veterinary diagnostic and related vaccines for canine and feline health.

Regional Outlook

North America was the largest region in the companion animal veterinary vaccines market in 2025. Asia-Pacific was the second-largest region in the companion animal veterinary vaccines market. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Companion Animal Veterinary Vaccines Market?

The companion animal veterinary vaccine market consists of sales of toxoid vaccines, viral vector vaccines, messenger RNA vaccines, and conjugated vaccines. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.